Breaking News
Investing Pro 0
Last Call for Cyber Monday! Save Now on Claim 60% OFF
Close

Mithra Pharmaceuticals Sa (MITRA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.18 -0.01    -0.84%
11:35:01 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Belgium
ISIN:  BE0974283153 
  • Volume: 41,139
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 1.17 - 1.19
Mithra Pharmaceuticals Sa 1.18 -0.01 -0.84%

MITRA Recent Sentiments

 
This page contains information on users’ sentiments for the Mithra Pharmaceuticals Sa stock, which are displayed both on charts of different periods of time and on a detailed table.
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
Nov 21, 2023 CM JQ   1.22 -3.28%
Nov 14, 2023 Baudouin Nisole   1.37 -13.87%
Nov 13, 2023 baudouin nisolle   1.32 -10.61%
Nov 03, 2023 Jozef De Neuter   1.28 +7.81%
Oct 27, 2023 Glinne Denis   1.27 Oct 27, 2023 @ 1.27 0.00%
Oct 27, 2023 Paul Raes   1.28 -7.81%
Oct 23, 2023 Rudi Geleleens   1.30 -9.23%
Oct 19, 2023 Dogay Gunes   1.14 Nov 07, 2023 @ 1.47 -28.95%
Oct 16, 2023 Sabe Vde   1.11 -6.31%
Oct 12, 2023 Thibault Gamme   1.19 +0.84%
Oct 12, 2023 Rg Goo   1.18 0.00%
Oct 11, 2023 Yaro Moonens   1.22 -3.28%
Oct 05, 2023 Marc Vertongen   1.28 Nov 20, 2023 @ 1.22 +4.69%
Oct 03, 2023 Bagher seyedi   1.17 +0.85%
Oct 03, 2023 Johan Lamaire   1.16 +1.72%
Oct 02, 2023 Philippe Jamet   1.30 -9.23%
Sep 29, 2023 Alain Goffaux   1.47 -19.73%
Sep 27, 2023 Bart Schepers   1.80 -34.44%
Sep 27, 2023 Denis Van Landuyt   1.89 -37.57%
Sep 26, 2023 Magnetic Couplers   1.83 -35.52%
Sep 25, 2023 Eric Weber   2.06 -42.72%
Sep 25, 2023 jean pierre vantuykom   2.08 -43.27%
Sep 13, 2023 christian Van der Aa   2.15 +45.12%
Sep 06, 2023 Samuel Raskin   2.05 +42.44%
Sep 01, 2023 Georges Hanin   2.15 -45.12%
Aug 28, 2023 Marc Mertens   2.24 -47.32%
Aug 25, 2023 Isabella Maes   2.22 -46.85%
Aug 14, 2023 Umberto Barbieri   2.60 -54.62%
Aug 09, 2023 lio onky   2.61 -54.79%
Aug 08, 2023 Michel François   2.58 +54.26%
Aug 08, 2023 Luc Cattrysse   3.17 -62.78%
Aug 08, 2023 Eddy Budo   3.62 -67.40%
Aug 08, 2023 Eddy Nijs   3.62 -67.40%
Aug 08, 2023 jo wu   3.45 -65.80%
Aug 07, 2023 vincent labarque   2.97 -60.27%
Aug 04, 2023 eve wesp   2.52 Aug 25, 2023 @ 2.23 -11.51%
Aug 04, 2023 Oli Rombaut   2.52 Sep 08, 2023 @ 2.06 -18.25%
Aug 04, 2023 Didier Boudart   2.55 -53.73%
Aug 03, 2023 ALEXANDRE BRUNEAU   2.28 -48.25%
Aug 03, 2023 Bruno Gilson   2.26 -47.79%
Aug 03, 2023 gerrit vlaeminck   2.18 -45.87%
Aug 03, 2023 Francois Caprace   2.10 -43.81%
Aug 02, 2023 Thierry Debus   1.89 -37.57%
Aug 02, 2023 Yasmina Raupova   1.90 -37.89%
Aug 01, 2023 Robert Brentjens   1.95 -39.49%
Aug 01, 2023 Patrice MARC   1.92 +38.54%
Jul 31, 2023 Marc Vertongen   1.71 Aug 17, 2023 @ 2.40 -40.35%
Jul 31, 2023 Louwrens Decreton   1.63 +27.61%
Jul 31, 2023 Loïc Simon   1.64 +28.05%
Jul 31, 2023 Grégory Maniglia   1.65 -28.48%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MITRA Comments

Write your thoughts about Mithra Pharmaceuticals Sa
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Golden Age
Global_K Oct 03, 2023 6:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I can't believe analysts are still giving a 12 month price target of 5.42, this sector is always with great (investor) risks
Jo Vanrutten
Jo Vanrutten Aug 10, 2023 3:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
a lot of potential for the Future
Grégory Vervoort
Grégory Vervoort Aug 12, 2022 4:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mega deal to come with catalent (CTLT) ?
Filip dB
Phildb Aug 10, 2022 3:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) *******hormonal contraceptive ring. Mayne Pharma anticipates the commercial launch of HALOETTE® ring by early calendar year 2023.
Filip dB
Phildb Aug 01, 2022 3:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Liege, Belgium, 01 August 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that its U.S. commercial partner, Mayne Pharma Group Limited (ASX: MYX), has entered into a new strategic collaboration with GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer (DTC) program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.
Filip dB
Phildb Jul 26, 2022 2:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
NEXSTELLIS® oral contraceptive now available in Australia26 July 2022, 07:30 CEST Adelaide, Australia and Liege, Belgium - Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXSTELLIS ® (14.2 mg of estetrol and 3 mg drospirenone tablets), the first-of-its-kind oral contraceptive with a novel estrogen, is now available in Australia. NEXTSTELLIS® unlocks a new era in contraception offering women and their healthcare providers a next generation birth control pill. Every woman’s body responds differently to contraceptive hormones and having a new estrogen available – E4 – opens up the possibility that more women will be able to find a combination that suits them. Mithra is excited to see the commercialisation of NEXTSTELLIS® contraceptive on a third continent. Leon Van Rompay, CEO Mithra Women’s Health
Filip dB
Phildb Jul 01, 2022 7:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
LDA Capital commits an amount of up to EUR 75 million in cash within a maximum of five years in exchange for new ordinary shares in Mithra. This is the fourth put option notice related to this agreement, leaving EUR 54 million available to Mithra.
Golden Age
Global_K May 06, 2022 5:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1 month later and 8.16, where's the bottom?
Golden Age
Global_K Apr 06, 2022 6:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
11.70, curious how low this can go. price now certainly does not represent future profits
Golden Age
Global_K Mar 08, 2022 3:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
14.00? Time to accumulate for a near future
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email